Overview
- Eli Lilly said it will begin enrolling patients next month for phase 3 studies of eloralintide following 48-week mid-stage results.
- The highest 9 mg dose produced a 20.1% average weight loss, with two-step escalation to 9 mg yielding 19.9% and a three-step regimen reaching 16.4%.
- Common adverse events were mild to moderate gastrointestinal symptoms and fatigue, concentrated at higher doses, with slower escalation reducing incidence and 1 mg and 3 mg rates similar to placebo.
- The 263-participant trial enrolled overweight adults with at least one obesity-related condition and excluded people with type 2 diabetes, and the drug is given once weekly.
- Investigators reported improvements in waist circumference, blood pressure, lipid and glycemic measures, and inflammation markers, with additional safety details to be presented at ObesityWeek in Atlanta.